License Number: 4648N.
Name: Mega Express, Inc.
Address: 6481 Orangethorpe Avenue, Suite 21, Buena Park, CA 90620.
Date Revoked: March 12, 2010.
Reason: Failed to maintain a valid bond.

License Number: 9800N.
Name: Unimax Express, Inc.
Address: 16901 South Keegan Avenue, Carson, Ca *90746*.
Date Revoked: March 30, 2010.
Reason: Failed to maintain a valid bond.

License Number: 11296N.
Name: Master Air Cargo, Inc.
Address: 8344 NW 30th Terrace, Miami, FL 33122.
Date Revoked: March 26, 2010.
Reason: Failed to maintain a valid bond.

License Number: 15581N.
Name: C & H Freight (USA), LLC dba Pacwest.
Address: 20437 South Western Avenue, Torrance, CA 90501.
Date Revoked: March 11, 2010.
Reason: Failed to maintain a valid bond.

License Number: 16611N.
Name: ENC New York Inc.
Address: 182–16 147th Street, Jamaica, NY 11413.
Date Revoked: March 12, 2010.
Reason: Failed to maintain a valid bond.

License Number: 016706N.
Name: Inter-trade Liner Shipping Co., Inc.
Address: 2111 West Cresent Avenue, Suite E, Anaheim, CA 92801.
Date Revoked: March 12, 2010.
Reason: Failed to maintain a valid bond.

License Number: 016914NF.
Name: Air Sea Cargo Network, Inc.
Address: 3480 Diablo Avenue, Hayward, CA 94545.
Date Revoked: March 12, 2010.
Reason: Failed to maintain valid bonds.

License Number: 017970N.
Name: Diarama Export, Inc.
Address: 2754 NW North River Drive, Suite 6, Miami, FL 33142.
Date Revoked: March 18, 2010.
Reason: Failed to maintain a valid bond.

License Number: 019032N.
Name: Fil-Am Cargo Corporation.
Address: 8340 Van Nuys Blvd., Unit L, Panorama, CA 91402.
Date Revoked: March 12, 2010.
Reason: Failed to maintain a valid bond.

License Number: 020347NF.
Name: Summit of Washington LLC.
Address: 8033 W. 224th Street, Bldg. F, Kent, WA 98032.
Date Revoked: March 12, 2010.
Reason: Failed to maintain valid bonds.

License Number: 020623N.
Name: Carie Freight, Inc.
Address: 1990 North Rosemead Blvd., Suite 201, South El Monte, CA 91733.
Date Revoked: January 31, 2010.
Reason: Surrendered license voluntarily.

License Number: 020764N.
Name: Get One Later, Inc. dba Omega Shipping West.
Address: 4379 Sheila Street, Los Angeles, CA 90023.
Date Revoked: October 4, 2010.
Reason: Failed to maintain a valid bond.

License Number: 020770NF.
Name: Four Point USA Inc.
Address: 6307 NW 99th Avenue, Doral, FL 33178.
Date Revoked: March 18, 2010.
Reason: Surrendered license voluntarily.

License Number: 020782NF.
Name: Euroworld Transport System America, Inc.
Address: 350 S. Northwest Highway, Suite 300, Park Ridge, IL 60068.
Date Revoked: March 23, 2010.
Reason: Surrendered license voluntarily.

License Number: 020849N.
Name: Master Freight America, Corp.
Address: 2025 NW 102nd Avenue, Unit 111, Miami, FL 33172.
Date Revoked: March 11, 2010.
Reason: Failed to maintain a valid bond.

License Number: 021258NF.
Name: Aero Logistics, LLC.
Address: 345 Swift Avenue, South San Francisco, CA 94080.
Date Revoked: March 1, 2010.
Reason: Surrendered license voluntarily.

License Number: 021270N.
Name: CT Telecom, Inc. dba JK Logis.
Address: 154–09 146th Avenue, 3rd Floor, Unit A, Jamaica, NY 11434.
Date Revoked: March 2, 2010.
Reason: Surrendered license voluntarily.

License Number: 021387N.
Name: Gaius Logistics Services LLC.
Address: 501 Penhorn Avenue, Unit 1, Secaucus, NJ 07094.
Date Revoked: March 14, 2010.
Reason: Failed to maintain a valid bond.

License Number: 021491F.
Name: Virginia A. Wodock dba I.F.S. of Indiana.
Address: 823 South Round Barn Road, Suite 2, Richmond, IN 47374.
Date Revoked: March 14, 2010.
Reason: Failed to maintain a valid bond.

License Number: 021896N.
Name: Logistic Freight Forwarders Group, Inc.
Address: 7232 NW 56th Street, Miami, FL 33166.
Date Revoked: March 25, 2010.
Reason: Failed to maintain a valid bond.

Sandra L. Kusumoto,
Director, Bureau of Certification and Licensing.

[FR Doc. 2010–9231 Filed 4–21–10; 8:45 am]
BILLING CODE P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Proposed Collection; Comment Request; Survey of Health Care Professionals' Awareness and Perceptions of the National Cancer Institute's Intramural Clinical Trials (NCI)

SUMMARY: In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the National Cancer Institute (NCI), the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

Proposed Collection: Title: The Survey of Health Care Professionals' Awareness and Perceptions of the National Cancer Institute's Intramural Clinical Trials (NCI) *Type of Information Collection Request:* New. *Need and Use of Information Collection:* To assess respondents' awareness and knowledge of NCI and measure awareness of NCI clinical trials at the NIH Clinical Center in Bethesda, Md. The survey will be disseminated electronically to members of the American Medical Association (AMA) with a certain primary specialties.

Frequency of Response: Yearly. *Affected Public:* Individual adults. *Type of Respondents:* Health care providers (AMA members who have allowed the use of their e-mail address).

The annual reporting burden is estimated at 28 hours (*see* Table below).

A.12–1—ESTIMATES OF ANNUAL BURDEN HOURS

Type of respondents	Number of respondents	Frequency of response	Average Time per response (minutes/hour)	Annual burden hours
Health care professionals who complete the survey	330	1	5/60 (0.083)	27.5
Totals	330	330		27.5

There are no Capital Costs, Operating Costs, and/or Maintenance Costs to report.

Request for Comments: Written comments and/or suggestions from the public and affected agencies should address one or more of the following points: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Susan McMullen, RN, Director, Office of Patient Outreach and Recruitment, Center for Cancer Research, NCI, Bloch Building 82, Room 101, MSC 8200, 9030 Old Georgetown Road, Bethesda, Maryland 20892 or by e-mailing your request, including your address to: *mcmulles@mail.nih.gov.*

Comments Due Date: Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.

Dated: April 15, 2010.

Vivian Horovitch-Kelley,

NCI Project Clearance Liaison, National Institutes of Health.

[FR Doc. 2010–9259 Filed 4–21–10; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2002–D–0094] (formerly Docket No. 02D–0049)

Draft Guidance for the Public, Food and Drug Administration Advisory Committee Members, and Food and Drug Administration Staff: Public Availability of Advisory Committee Members' Financial Interest Information and Waivers; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for the public, FDA advisory committee members, and FDA staff entitled "Guidance for the Public, FDA Advisory Committee Members, and FDA Staff: Public Availability of Advisory Committee Members' Financial Interest Information and Waivers." This draft guidance is intended to help the public, FDA advisory committee members, and FDA staff to understand and implement FDA procedures regarding public availability of information regarding certain financial interests and waivers granted by FDA to permit individuals to participate in an advisory committee meeting. The draft guidance would provide even greater transparency to FDA's advisory committee process than current guidance. The draft guidance announced in this notice, when finalized, would replace guidance of the same title dated August 2008.

DATES: Although you may comment on any guidance at any time (see 21 CFR 10.115(g)(5)), to ensure that the agency considers your comment on this draft guidance before it begins work on the final version of the guidance, submit written or electronic comments on the draft guidance by June 21, 2010.

ADDRESSES: Submit written requests for single copies of the guidance to Office of Special Medical Programs, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 5103, Silver Spring, MD 20993. Send one self-addressed adhesive label to assist that office in processing your requests. Submit phone requests to 800–835–4709 or 301–827–1800. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the guidance document.

Submit written comments on the draft guidance to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to *http://www.regulations.gov*.

FOR FURTHER INFORMATION CONTACT: Michael Ortwerth, Office of Special Medical Programs, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 5103, Silver Spring, MD 20993, 301–796–8220.

SUPPLEMENTARY INFORMATION:

I. Background

FDA is announcing the availability of a draft guidance entitled "Guidance for the Public, FDA Advisory Committee Members, and FDA Staff: Public Availability of Advisory Committee Members' Financial Interest Information and Waivers." FDA's advisory committees provide independent and expert advice on scientific, technical, and policy matters related to the development and evaluation of products regulated by FDA. FDA implements a rigorous process for soliciting and vetting candidates for advisory committee meetings to minimize any potential for financial conflicts of interest. The agency is authorized by statute to grant waivers to allow individuals with potentially conflicting financial interests to participate in meetings where we conclude, after close scrutiny, that certain criteria are met. (See 18 U.S.C. 208(b)(1) and (b)(3), section 712(c)(2)(B) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 379d-1) (added by the Food and Drug Administration Amendments Act of 2007, Public Law No. 110–85), and section 701 (21 U.S.C. 371) (effective October 1, 2007)).

In January 2002, FDA issued the "Draft Guidance on Disclosure of Conflicts of Interest for Special